Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model
- 7 August 2012
- journal article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 97 (10) , 4393-4401
Abstract
The PNP/6-methylpurine 2′-deoxyriboside (6MePdR) system is an efficient gene-directed enzyme prodrug therapy system with significant antitumor activities. In this system, Escherichia coli purine nucleoside phosphorylase (ePNP) activates nontoxic 6MePdR into potent antitumor drug 6-methylpurine (6MeP). The Salmonella typhimurium PNP (sPNP) gene has a 96-% sequence homology in comparison with ePNP and also has the ability to convert 6MePdR to 6MeP. In this study, we used tumor-targeting S. typhimurium VNP20009 expressing endogenous PNP gene constitutively to activate 6MePdR and a combination treatment of bacteria and prodrug in B16F10 melanoma model. The conversion of 6MePdR to 6MeP by S. typhimurium was analyzed by HPLC and the enzyme activity of sPNP was confirmed by in vitro (tetrazolium-based colorimetric assay) MTT cytotoxicity assay. After systemic administration of VNP20009 to mice, the bacteria largely accumulated and specifically delivered endogenous sPNP in the tumor. In comparison with VNP20009 or 6MePdR treatment alone, combined administration of VNP20009 followed by 6MePdR treatment significantly delayed the growth of B16F10 tumor and increased the CD8+ T-cell infiltration. In summary, our results demonstrated that the combination therapy of S. typhimurium and prodrug 6MePdR is a promising strategy for cancer therapy.Keywords
This publication has 32 references indexed in Scilit:
- Bacteria-Induced Gap Junctions in Tumors Favor Antigen Cross-Presentation and Antitumor ImmunityScience Translational Medicine, 2010
- Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in miceBritish Journal of Cancer, 2009
- Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene TherapyClinical Cancer Research, 2008
- Tumor-targeting prodrug-activating bacteria for cancer therapyCancer Gene Therapy, 2008
- Tumor‐targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low‐dose metronomic regimens in a murine melanoma modelInternational Journal of Cancer, 2007
- Using attenuated salmonella typhi as tumor targeting vector for MDR1 siRNA delivery: An experimental studyCancer Biology & Therapy, 2007
- Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenograftsCancer Gene Therapy, 2007
- Experimental studies onPNP suicide gene therapy of hepatomaCurrent Medical Science, 2005
- Transcriptional tumor‐selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapyThe Journal of Gene Medicine, 2004
- In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cellsGene Therapy, 2000